| 证券代码 | CORI.O |
| 证券名称 | Corium International Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2014-04-03 |
| 首发价格(元) | 8 USD |
| 首发数量(股) | 6500000 |
| 首发募资额(元) | 52,000,000.00 USD |
| 首发主承销商 | Jefferies LLC,Leerink Partners LLC |
| 货币单位 | USD |
| 公司名称 | Corium International, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 235 Constitution Drive, Menlo Park, California, USA |
| 成立日期 | 1995 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.coriumgroup.com |
| 电话 | +1 (650) 298-8255 |
| 传真 | +1 (650) 298-8012 |
| 公司简介 | Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company’s broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer’s disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Teva Pharmaceuticals, Endo Pharmaceuticals and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. |